Anti-inflammatory solution

Abstract

The present invention provides a method for preventing or treating an inflammatory response, condition or disease in a mammal comprising administering an effective amount of a dilute stabilised hypochlorite solution to said mammal in need thereof as well as a means for mixing and administering fresh, dilute stabilised hypochlorite solution to the site where it is needed.

1 . A method for preventing or treating an inflammatory response, condition or disease in a mammal comprising administering an effective amount of a dilute stabilised hypochlorite solution to said mammal in need thereof. 
     
     
         2 . The method according to  claim 1 , wherein the inflammatory response is in uncontaminated or non-infected surgical sites, wounds, trauma sites or surface inflammatory or inflammatory lesions where there is no infection, or it is an inflammatory pain response. 
     
     
         3 . The method according to  claim 2 , wherein the inflammatory response is in an uncontaminated or non-infected surgical site or wound, preferably a non-healing wound or an oral wound. 
     
     
         4 . The method according to  claim 2 , wherein the wound or surface inflammatory or inflammatory lesion is an ulcer. 
     
     
         5 . The method according to  claim 2 , wherein the wound or surface inflammatory or inflammatory lesion is a venous ulcer. 
     
     
         6 . The method according to  claim 2 , wherein the wound or surface inflammatory or inflammatory lesion is a venous leg ulcer. 
     
     
         7 . The method according to  claim 1 , wherein the inflammatory condition is an inflammatory skin condition, an inflammatory condition or an inflammatory pain response. 
     
     
         8 . The method according to  claim 7 , wherein the inflammatory skin condition or inflammatory pain response is selected from the group consisting of mouth ulcers, eczema, psoriasis, allergic dermatitis, contact inflammatory dermatitis, stasis dermatitis, seborrheic dermatitis, inflammatory nociceptive pain, inflammatory neuropathic pain, inflammatory stomatitis, rheumatoid arthritis, Alzheimer's disease, rosacea and lupus, preferably mouth ulcers, eczema, psoriasis, inflammatory nociceptive pain and inflammatory neuropathic pain. 
     
     
         9 . The method according to  claim 1 , wherein the hypochlorite solution is sodium hypochlorite in a concentration range of 0.005-0.2 wt %, preferably 0.05-0.1 wt %. 
     
     
         10 . The method according to  claim 1 , wherein the dilute hypochlorite solution further comprises sodium chloride. 
     
     
         11 . The method according to  claim 1 , wherein said dilute hypochlorite solution further comprises sodium chloride in a concentration range of 0.5-1.5 wt %, preferably in a concentration range of 0.8-1.0 wt %. 
     
     
         12 . The method according to  claim 1 , wherein said dilute stabilised sodium hypochlorite solution is buffered to a pH of from 5-11, preferably 6-10. 
     
     
         13 . The method according to  claim 1 , further comprising an indicator to show that the dilute stabilised sodium hypochlorite solution is fresh and active. 
     
     
         14 . The method according to  claim 1 , further comprising an indicator to show that the dilute stabilised sodium hypochlorite solution is fresh and active, wherein said indicator is a dye or a flavour or a combination thereof. 
     
     
         15 . The method according to  claim 1 , further comprising an indicator to show that the dilute stabilised sodium hypochlorite solution is fresh and active, wherein said indicator also shows that the disinfectant is at the correct dilution. 
     
     
         16 . The method according to  claim 1 , wherein the mammal is a human. 
     
     
         17 . A concentrated stabilised sodium hypochlorite solution to be diluted before use in the prevention or treatment of an inflammatory response, condition or disease in a mammal, preferably a human. 
     
     
         18 . The concentrated stabilised sodium hypochlorite solution to be diluted before use according to  claim 17 , wherein the inflammatory response is in uncontaminated or non-infected surgical sites, wounds, trauma sites or surface inflammatory lesions where there is no infection, or it is an inflammatory pain response. 
     
     
         19 . The concentrated stabilised sodium hypochlorite solution to be diluted before use according to  claim 18 , wherein the inflammatory response is in an uncontaminated or non-infected surgical site or wound, preferably a non-healing wound or an oral wound. 
     
     
         20 . The concentrated stabilised sodium hypochlorite solution to be diluted before use according to  claim 18 , wherein the wound or surface inflammatory or inflammatory lesion is an ulcer, particularly a venous ulcer. 
     
     
         21 . The concentrated stabilised sodium hypochlorite solution to be diluted before use according to  claim 18 , wherein the wound or surface inflammatory or inflammatory lesion is a venous leg ulcer. 
     
     
         22 . The concentrated stabilised sodium hypochlorite solution to be diluted before use according to  claim 17 , wherein the inflammatory condition is an inflammatory skin condition or an inflammatory pain response. 
     
     
         23 . The concentrated stabilised sodium hypochlorite solution to be diluted before use according to  claim 17 , wherein the inflammatory skin condition or inflammatory pain response is selected from the group consisting of mouth ulcers, eczema, psoriasis, allergic dermatitis, contact inflammatory dermatitis, stasis dermatitis, seborrheic dermatitis, inflammatory nociceptive pain, inflammatory neuropathic pain, inflammatory stomatitis, rheumatoid arthritis, Alzheimer's disease, rosacea and lupus, preferably mouth ulcers, eczema, psoriasis, inflammatory nociceptive pain and inflammatory neuropathic pain. 
     
     
         24 . The concentrated stabilised sodium hypochlorite solution to be diluted before use according to  claim 17 , wherein the concentration of hypochlorite is in the range of 0.5-3 wt % and the solution is buffered to a pH of from 9-15, preferably 11-13. 
     
     
         25 . A method for preventing or treating an inflammatory response, condition or disease in a mammal according to  claim 1 , wherein said dilute stabilised hypochlorite solution is administered using a portable device for mixing a dilute hypochlorite solution comprising:
 a disinfectant reservoir holding hypochlorite solution,   a chamber which is connected to said hypochlorite reservoir and which is for holding a predetermined amount of dilutant, and   hypochlorite discharging means for discharging a predetermined amount of said hypochlorite solution from said first reservoir to be mixed with said predetermined amount of dilutant, whereby said device provides the dilute hypochlorite solution at a fixed dilution determined by the ratio of the predetermined amount of said hypochlorite solution to the predetermined amount of dilutant.   
     
     
         26 . The method according to  claim 25 , wherein the concentration of the hypochlorite solution in the disinfectant reservoir is from 0.5 to 3 wt %. 
     
     
         27 . The method of  claim 26 , wherein said portable device is provided with a reservoir for a sodium chloride stabilising solution having a concentration of 10 to 18 wt %, said sodium chloride solution being deliverable from said reservoir to the chamber in a precise amount to mix with the sodium hypochlorite to give stabilisation of the measured amount of sodium hypochlorite solution. 
     
     
         28 . The method according to  claim 25 , wherein the portable device is configured to deliver the dilute disinfectant solution to wounds. 
     
     
         29 . The method according to  claim 28 , wherein the chamber is attached around the wound to retain the dilute disinfectant solution over the wound. 
     
     
         30 . The method according to  claim 25 , wherein the mammal is a human.